مواقع التدريسيينجامعة الكوفة
بشائر مرتضى محمد باقر بحرالعلوم
مدرس

بشائر مرتضى محمد باقر بحرالعلوم

English Version
0بحث منشور
0محاضرة
0اهتمام بحثي
0خبر

الملف الشخصي

التحصيل العلمي:
.بكلوريوس في الصيدلة حاصلة عليها من كلية الصيدلة / جامعة الكوفة لسنة 2007-2008 ومن الطلبة الاوائل على الدفعة
.شهادة الماجستير في الادوية والعلاجيات حاصلة عليها من كلية الطب/ جامعة الكوفة لسنة 2015 وبتسلسل الاول
. شهادة الدكتوراه في الادوية والعلاجيات حاصلة عليها من كلية الطب / جامعة الكوفة لسنة 2020 وبتسلسل الاول
العمل:
.مقيمة دورية في مستشفى الحكيم 2009-2010
. معيدة في فرع الصيدلة السريرية كلية الصيدلة جامعة الكوفة من 2012-2013
. مدرس مساعد في فرع الصيدلة السريرية كلية الصيدلة جامعة الكوفة من 2016 للان

الاهتمامات البحثية

3

البحوث المنشورة

9
2023

The prevalence study of patients infected with pyelonephritis by in Al-Najaf Governorate, Iraq

الباحثونBashaer M. Muhammad-Baqir ، Abdalmahdi Abdalrasul Fattah2 , Dhafer Rahman Abed Al-janabi3 , and Ahmed Abduljabbar Jaloob Aljanaby4
المجلةBIO Web of Conferences
مختصر البحث

Abstract. The study aimed at the prevalence of pyelonephritis and its association with some kidney diseases, function or structure, in Iraq, specifically in the province of Najaf, for a period of 16 months, from 2/1/2022 to 1/5/2023, where 1255 samples of males and females of different ages were collected, and the patients were divided into several groups depending on time, gender, residence, age and disease. Regarding the disease, there are individuals who only have pyelonephritis and their number was 277 (18%), while the rest of the patients were 1028 (82%) who had kidney problems, whether functional or immunological, which is kidney failure and renal syndrome, kidney transplantation and lupus erythematous. The most common is pyelonephritis associated with renal failure or insufficiency, with a number of 768.)%95( Also, the results showed that the month of April for the year 2022 obtained the most samples, with a number of 109 (8.69%) samples. with regard to gender, females were generally more susceptible to infection than males, reaching 55%. As for housing, most patients lived in urban areas. In contrast to rural areas, where their percentage was low (40%), and therefore people should be educated and urged to review the hospital and specialist doctors when they feel any symptoms related to the kidneys, so that they do not suffer from failure later.

2021

Healthy foods that might be helpful in fighting COVID-19

الباحثونNajah R. Hadi1 ، Bashaer M. Muhammad-Baqir2 , Mustafa H. Ahmed 3 , Russell Setright4
المجلةAnnals of R.S.C.B
مختصر البحث

Coronavirus disease (COVID-19) is caused by SARS-CoV-2, which is a novel corona virus that can cause remarkable infectious disease. This virus can transfer easily from person to another. The first case was documented in December 2019, in Wuhan/ Hubei, China. The WHO declared the disease as a global pandemic on 11 March 2020. Unfortunately, the world has to try by prevention measures to contain the disease as much as possible because the medical establishments has failed so far to provide any reliable treatment for COVID-19.Enhancement of immune function is of high importance since the immune system is actually the force that preserves the integrity of the body by resisting pathological agents and microorganisms, including viruses, bacteria, fungi. Adequate nutrition should be paid enough attention to maintain body’s defenses and immune mechanisms. This can be achieved by providing healthy diet and giving balanced level of vitamins, minerals, water, and calories. The prevention and management of viral infections require balanced nutrition, which is also important for enhancing the organism’s immunity against viral infections. Immune dysfunction can lead to increased susceptibility to infectious diseases. Such event is expected to happen when specific nutritional deficiencies and dietary insufficiencies occur, including deficiency of vitamin C, vitamin E, vitamin A, omega-3 fatty acids, zinc, selenium, and proteins.

2021

Inflammatory Response to Percutaneous Coronary Intervention

الباحثونNajah R. Hadi1* ، Bashaer M. Muhammad-Baqir2 and Mustafa H. Ahmed3
المجلةB P international
مختصر البحث

Atherosclerosis is now considered an inflammatory disease. Inflammation has been demonstrated to contribute to its initiation as well as its progression. Coronary artery disease is a leading cause of death worldwide. The treatment of coronary artery disease has been transformed by the introduction of percutaneous coronary intervention, which remains the focus of intensive research and development. Percutaneous coronary intervention produces a significant inflammatory reaction in the injured vessel wall, that may lead to the development of neointimal thickening and restenosis. Balloon coronary angioplasty or stent deployment is associated with significant platelet activation, which promotes leukocyte recruitment to the injured vessel wall and it has also been shown to induce an inflammatory response. Inflammation plays a major role in determining stent restenosis via neointimal proliferation. Several acute-phase reactants, cytokines, and soluble cellular adhesion molecules have been implicated in this inflammatory process. Moreover, increased inflammatory protein levels in peripheral blood have been found in atherosclerotic diseases, such as unstable angina pectoris, acute myocardial infarction and angiographically documented coronary heart disease. Thus, high levels of acute phase reactants correlate with a worse prognosis. Conclusion: Percutaneous coronary intervention induces a significant inflammatory reaction in the injured vessel wall that leads to the development of neointimal thickening and restenosis. Post procedural inflammatory response in patients undergoing coronary intervention reveal a wide range of mechanisms, including mechanical disruption of atherosclerotic plaque, arterial wall injury, myocardial necrosis due to distal embolization and endothelial dysfunction, and release of inflammatory factors followed by leukocytes and platelet activation along with the ischaemiareperfusion injury. The inflammatory reaction plays an equally important role as arterial injury in neointimal formation after coronary stenting, and that anti-inflammatory approaches may be of value to reduce in-stent restenosis.

2020

Acute Inflammatory Response after Bioresorbable Coronary Scaffold Implantation and impact of Trimetazidine

الباحثونHUSSEIN A. ALSALKHI، AHMED N. RAJEEB 2 , MUSTAFA H. AHMED 3 , NAJAH R. HADI 4 *, KHALID I. AMBER 5 , BASHAER M. MUHAMMAD-BAQIR 6
المجلةInternational Journal of Pharmaceutical Research
مختصر البحث

ABSTRACT Background: Coronary intervention is related to local vascular and systemic inflammation that leads to the stimulation of inflammatory reaction, caused by the rupture of the atherosclerotic plaque and the tunica media fallowing extension of the stent and insertion of a metallic foreign body. Arterial wall damage occurs in addition to the release of inflammatory and chemoattractant factors which stimulate an inflammatory response, leading to leukocyte and platelet activation. Bioresorbable vascular Scaffold (BVS) is considered the fourth revolution in interventional cardiology. It has introduced a novel technology in the treatment of coronary artery disease (CAD). Trimetazidine (TMZ) is an anti-ischemic agent which minimizes the myocardial damage induced by the percutaneous coronary intervention (PCI). Objective: To assess the effect of TMZ on the acute inflammatory response after BVS implantation in patients with CAD. Patients and Methods: A total of 40 diabetic patients with stable coronary artery disease were assigned into two groups: the control group and TMZ treated group. Both groups were admitted to AL-Najaf center for cardiac surgery and Tran’s catheter therapy. Thus, patients under went elective coronary scaffold implantation. Serum blood was collected from peripheral vein before implantation, 12 hrs and 24 hrs after implantation. Collected samples were used to measure IL-8, hs-CRP, cTn-I, MMP-9 and VCAM-1 levels by sand wichELISA method in addition to determine the WBC count. Results. Scaffold implantation produced significant changes in serum levelIL-8, hs-CRP, cTn-I, WBC and VCAM-1(p<0.05).However, no significant change in serum level MMP-9was found (p>0.05).On the other hand, TMZ treatment produced a significant decrease in cTn-I, hs-CRP levels and the WBC count (p<0.05).No significant changes in serum IL-8, MMP-9and VCAM-1were found (p>0.05). Conclusion: Trimetazidine reduced the systemic inflammatory response induced by implantation of Bioresorbable coronary scaffold.

2020

Acute Inflammatory Response after Novolimus Eluting Bioresorbable Scaffold and Novolimus Eluting Stent Implantation in Al-Najaf Cardiac Center Patients: A Comparative Study

الباحثونYasseen YA ، Rajeeb AN2 , Ahmed MH3 , Amber KI4 , Aziz ND5 , Muhammad-Baqir BM6 and Hadi NR7 *
المجلةLa Prensa Medica Argentina
مختصر البحث

Abstract Background: Inflammation plays an important role in the development of acute coronary syndromes (ACS) and post percutaneous coronary intervention (PCI) response due to vascular injury triggered by intervention procedures. During the thrombus formation, the progression of inflammation, neointimal proliferation, a lymphocyte/macrophage infiltration can occur either immediately after or in the hours following the series as an inflammatory response to coronary stent implantation. Bioresorbable vascular scaffold (BVS) thrombosis is a problem with this device in both acute to very late thrombosis. Acute and sub-acute BVS thrombosis is linked with conditions of implantation as shown in drug-eluting stent (DES). Objective: To assess the differences between the two types of coronary systems, Novolimus Bioresorbable scaffold and Novolimus eluting stent implantation associated with acute inflammatory response triggered by percutaneous coronary intervention in coronary artery disease patients. Patients and Methods: A total of forty-four diabetic patients (type II) with unstable angina (29 men and 15 women, aged 43 to 70 years old) were included in this study. All patients submitted to elective PCI at AL-Najaf center for cardiac surgery and Tran’s catheter therapy between January and July 2015. The patients were randomized into two groups in a single-blind study. (Group 1) includes Twenty diabetes patients with coronary artery stenosis undergoing Novolimus Bioresorbable coronary scaffold implantation (Group 2) includes Twenty four diabetes patients with coronary artery stenosis undergoing Novolimus eluting stent implantation. Serum blood samples were drawn from peripheral vein directly before implantation, as well as 12 and 24 hours after implantation to use for measurement of IL-6, PTX3, MMP-9, cTn-I, and C5a by sandwich ELISA method. Results: This comparison of Novolimus eluting coronary stent and Novolimus Bioresorbable coronary scaffold implantation showed a significant increase in serum levels of IL-6, PTX3 at 12 and 24 hrs. and MMP-9 at 24 hrs. (p<0.05) in group 1 as compared with group 2, while the serum levels of cTn-I and C5a were insignificantly changed between two groups of coronary systems (p>0.05). Conclusions: The Novolimus Bioresorbable scaffold with thick strut cause more marked inflammatory response as compared with Novolimus eluting stent with thin strut.

2020

The role of Trimetazidine in prevention of contrast induced nephropathy in diabetic patients with renal insufficiency undergoing cardiac intervention

الباحثونAhmed N. Rajeeb1 ، Khalid I. Amber2, Najah R. Hadi3, Hussein A. Alsalkhi4, Bashaer M. Muhammad-Baqir5, Mustafa H. Ahmed6
المجلةSystematic Review Pharmacy
مختصر البحث

ABSTRACT This study aims to assess the possible protective role of Trimetazidine in the prevention of contrast induced nephropathy in patients with renal impairment undergoing coronary angiography or percutaneous coronary intervention. This was a randomized single-blind clinical trial study. A total of 100 consecutive diabetic patients with symptomatic ischemic heart disease and chronic kidney disease (CKD) were subjected to an elective percutaneous coronary intervention, at ALSADR teaching hospital /Al- Najaf Center for Cardiac surgery and Tran Catheter Therapy, Najaf, Iraq, in period between May and December 2018. The Patients were divided into two groups: Group I-Control Group (n=45) these patients with chronic kidney disease and critical coronary stenosis and they were needed to be subjected to coronary intervention. Group II- Treatment Group (n=44) also these patients with chronic kidney disease and critical coronary stenosis and they were need to be subjected to coronary intervention and treated with 35 mg tablet /twice daily of Trimetazidine for the period of three days. Trimetazidine significantly reduce the elevation in serum level of monocyte chemo tactic protein1, expression of Toll-like receptor 2 and the urine levels of kidney injury molecule-1,F2-isoprostanes (p<0.05) while insignificantly reduce the elevation in serum level of creatinine . (p > 0.05). Our study concluded that Trimetazidine reduce the acute kidney injury response and systemic inflammatory response induced by contrast administration after coronary intervention.

2020

Impact of Trimetazidine on Incidence of Contrast Induced Nephropathy in Diabetic Patients with Renal Insufficiency Undergoing Percutaneous Coronary Intervention

الباحثونNajah R. Hadi1* ، Khalid I. Amber2, Hussein A. Alsalkhi3, Bashaer M. Muhammad-Baqir4, Mustafa H. Ahmed5
المجلةSystematic Review Pharmacy
مختصر البحث

ABSTRACT The main objective of this study is to assess the possible protective role of Trimetazidine in the prevention of contrast induced nephropathy in patients with renal impairment undergoing coronary angiography or percutaneous coronary intervention. This was a randomized single-blind clinical trial study. A total of 100 consecutive diabetic patients with symptomatic ischemic heart disease and chronic kidney disease (CKD) were subjected to an elective percutaneous coronary intervention, at ALSADR teaching hospital /Al- Najaf Center for Cardiac surgery and Tran Catheter Therapy, Najaf, Iraq, in period between May and December 2018. The Patients were divided into two groups: Group I-Control Group (n=45) these patients with chronic kidney disease and critical coronary stenosis and they were needed to be subjected to coronary intervention. Group IITreatment Group (n=44) also these patients with chronic kidney disease and critical coronary stenosis and they were need to be subjected to coronary intervention and treated with 35 mg tablet /twice daily of Trimetazidine for the period of three days , starting 48 hours before surgical procedure and for 24 hours post the procedure. Trimetazidine significantly reduce the elevation in serum levels of nuclear factor kappa B , high-mobility group box 1, expression of Tolllike receptor 2 (p<0.05) while insignificantly reduce the elevation in serum levels of creatinine and urine level of Neutrophils gelatinaseassociated lipocalinis (p > 0.05). Our study concluded that Trimetazidine reduce the acute kidney injury response and systemic inflammatory response induced by contrast administration after coronary intervention.

2016

Impact of Coronary Novolimus Bioresorbable Scaffold & Novolimus Eluting Stent Implantation on the Acute Inflammatory Response in Diabetic Patients with Coronary Artery Disease

الباحثونKhalid I. Amber ، Najah R Hadi, Bashaer M Muhammad Baqir , Ahmed Regeeb
المجلةJournal of Cardiology & Current Research
مختصر البحث

Abstract Background: The most effective treatment for coronary arteries revascularization in patients suffering from coronary artery disease (CAD) is percutaneous coronary intervention (PCI). However, when a coronary stent implantation is applied to the affected coronary artery, a mechanical injury to the arterial wall may occur causing a local inflammatory response. As a result, immediately after a PCI, a rapid increase in circulatory inflammatory markers may occur. Objective: This study was undertaken to investigate the effect of Novolimus bioresorbable coronary scaffold and Novolimus eluting stent on the acute inflammatory response after implantation in patients with coronary artery disease. Patients and Methods: Between January and July 2015, 44 type II diabetic patients (29 male; 15 female ) with ischemic heart disease (unstable angina) were randomly assigned into two groups: Group1: Novolimus eluting Bioresorbable coronary scaffold implantation group (20 patients) and Group 2 :Novolimus eluting coronary stent implantation group (24 patients) .They were admitted to AL-Najaf center for cardiac surgery and trans catheter therapy and submitted to elective coronary stent implantation. Blood was drawn from peripheral vein directly before implantation, 12 hrs and 24 hrs after implantation and used to measure IL-8, hs-CRP, MMP-9, cTn-I and VCAM-1 levels by sandwich ELISA method. Results: Inflammatory markers in patients subjected to elective Novolimus eluting bioresorbable coronary scaffold were found to be significantly higher than those subjected to Novolimus eluting stent. Specifically (IL-8) levels were found to be elevated at (12, 24) hrs. Levels of hs-CRP, MMP-9, VCAM-1 were found to be elevated at 24 hrs (p< 0.05) whereas the levels of cTn-I were found to be insignificantly increased (p>0.05) at (12, 24) hrs. Conclusions patients treated with BRS showed significantly higher increase in inflammatory mediators as compared to patients treated with Novolimus eluting stent.

2016

Trimetazidine attenuates the acute inflammatory response induced by Novolimus eluting bioresorbable coronary scaffold implantation

الباحثونKhalid I. Amber a، Najah R. Hadi b, Bashaer M. Muhammad-Baqir c, Dina A. Jamil d, Hayder A. Al-Aubaidy
المجلةInternational Journal of Cardiology
مختصر البحث

scaffold implantation after a course treatment with trimetazidine (35 mg tablet/twice daily for 4 days). Methods: This was a randomized single blind study. Forty diabetic patients with critical coronary stenosis were subjected to elective coronary scaffold implantation in Al-Najaf Center for Cardiac Surgery and Trans-Catheter Therapy, Najaf, Iraq, between January and July 2015. All patients were informed about the nature of the study and they signed the consent form before they included in the study. Patients were randomly allocated into the two study groups: Group 1 included 20 patients who did the elective coronary scaffold implementation without trimetazidine medication. Group 2 included 20 patients who did the elective coronary scaffold implementation with a course of the trimetazidine (35 mg tablet/twice daily for 4 days). Results: There were significant reduction in the levels of the interleukin-6 and cardiac troponin-I in the trimetazidine-treated group (group 2) compared to the control group (group 1) (P b 0.001), after 12 h and 24 h post-operative. This was associatedwith a significant rise in the levels of interleukin 10 in group 2 compared to group 1 (P b 0.001). Pentraxin-3 was significantly reduced in group 2 but only 24 h post-operative (P b 0.006). Conclusion: Our study concluded that trimetazidine minimizes the acute inflammatory response occurred due to systemic release of inflammatory markers into blood in diabetic patients undergoing elective Novolimus bioresorbable coronary scaffold implementation.

المحاضرات

19

Cell ,tissue and organ

Medical Terminology

Words parts pertaining to cell, tissue and organ

Medical Terminology

Cardiovascular system

Medical Terminology

The vascular system

Medical Terminology

The respiratory system

Medical Terminology

The nervous system

Medical Terminology

Asthma

Clinical pharmacy

COPD

Clinical pharmacy

Tuberculosis

Clinical pharmacy

Respiratory tract infection

Clinical pharmacy

Peptic ulcer

Clinical pharmacy

D.M

Clinical pharmacy

Obstetric history

Hospital training

UTI,Abortion

Hospital training

Acute kidney injery

Applied Therapeutics

Chronic kidney disease

Applied Therapeutics

urinary incontinence

Applied Therapeutics

Benign prostatic hyperplasia

Applied Therapeutics

Urinary tract infection

Applied Therapeutics

الأخبار والإعلانات

1
الأخبار 2023-09-07

استخدام ابر السكسندا في مجال تخفيض الوزن

حققت ابر ساكسيندا نجاحا واسعا في وقتا صغير بعد تجربة العديد من السيدات التي عانين من زيادة أوزانهن خاصة بعد الحمل والولادة. تم اعتماد ابر التنحيف من ساكسيندا من قبل هيئة الغذاء والدواء الأمريكية، إذ أنه آمن تماما ولا توجد منها أية أضرار.يظهر مفعولها سريعا بعد حوالى ستة أسابيع. يستمر مفعول إبر التنحيف من ساكسيندا لمدة عامين وقد يمتد إلى أربعة أعوام.

عرض التفاصيل